心脏瓣膜门诊随访的无症状主动脉瓣狭窄患者结局
该研究基于心脏瓣膜门诊国际数据库,纳入1375例无症状且左室射血分数保留的主动脉瓣狭窄患者,中位随访27个月,发现严重狭窄患者2年无主动脉瓣置换生存率仅54%,峰值流速>5 m/s或LVEF<60%与死亡风险增加相关。
要点
- 无症状严重主动脉瓣狭窄患者2年无主动脉瓣置换生存率为54%,4年为32%。
- 峰值主动脉射流速度>5 m/s或LVEF<60%与全因和心血管死亡风险增加相关。
- 猝死 crude 率为0.65%,总体生存率与既往系列相似。
核心结论
- 无症状主动脉瓣狭窄患者在瓣膜中心随访时猝死风险低,总体生存率与既往报道相似。
- 基线严重狭窄且峰值流速≥5.0 m/s或LVEF<60%的患者即使接受主动脉瓣置换,全因和心血管死亡风险仍增加。
研究设计与样本
- 研究为注册登记研究,合并欧洲、加拿大和美国10个心脏瓣膜门诊前瞻性收集的机构数据库数据。
主要发现
- 共纳入1375例患者,男性834例(60.7%),平均年龄71(13)岁,其中861例(62.6%)为严重主动脉瓣狭窄(瓣面积<1.0 cm2)。
- 医疗管理期间平均随访27(24)个月,2年、4年、8年总体生存率分别为93%(1%)、86%(2%)、75%(4%)。
- 104例(7.6%)在观察期间死亡,其中57例(54.8%)死于心血管原因,猝死粗率为0.65%。
- 542例(39.4%)接受主动脉瓣置换,其中388例(71.6%)为入组时严重狭窄,154例(28.4%)为中度狭窄进展为严重狭窄。
- 基线严重狭窄患者2年和4年无主动脉瓣置换生存率分别为54%(2%)和32%(3%),接受置换者30天术后死亡率为0.9%。
关键数值与推荐
- 主动脉瓣置换指征基于当前指南推荐。
- 基线严重狭窄患者中,峰值主动脉射流速度>5 m/s和LVEF<60%与未行主动脉瓣置换时的全因和心血管死亡相关。
- 上述因素也与基线严重狭窄接受主动脉瓣置换(外科310例,经导管78例)患者的术后死亡相关。
临床怎么用
- 对无症状严重主动脉瓣狭窄患者,应密切监测峰值主动脉射流速度和LVEF。
- 峰值流速≥5.0 m/s或LVEF<60%的高危患者,可考虑早期干预的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The natural history and the management of patients with asymptomatic aortic stenosis (AS) have not been fully examined in the current era. OBJECTIVE: To determine the clinical outcomes of patients with asymptomatic AS using data from the Heart Valve Clinic International Database. DESIGN, SETTING, AND PARTICIPANTS: This registry was assembled by merging data from prospectively gathered institutional databases from 10 heart valve clinics in Europe, Canada, and the United States. Asymptomatic patients with an aortic valve area of 1.5 cm2 or less and preserved left ventricular ejection fraction (LVEF) greater than 50% at entry were considered for the present analysis. Data were collected from January 2001 to December 2014, and data were analyzed from January 2017 to July 2018. MAIN OUTCOMES AND MEASURES: Natural history, need for aortic valve replacement (AVR), and survival of asymptomatic patients with moderate or severe AS at entry followed up in a heart valve clinic. Indications for AVR were based on current guideline recommendations. RESULTS: Of the 1375 patients included in this analysis, 834 (60.7%) were male, and the mean (SD) age was 71 (13) years. A total of 861 patients (62.6%) had severe AS (aortic valve area less than 1.0 cm2). The mean (SD) overall survival during medical management (mean [SD] follow up, 27 [24] months) was 93% (1%), 86% (2%), and 75% (4%) at 2, 4, and 8 years, respectively. A total of 104 patients (7.6%) died under observation, including 57 patients (54.8%) from cardiovascular causes. The crude rate of sudden death was 0.65% over the duration of the study. A total of 542 patients (39.4%) underwent AVR, including 388 patients (71.6%) with severe AS at study entry and 154 (28.4%) with moderate AS at entry who progressed to severe AS. Those with severe AS at entry who underwent AVR did so at a mean (SD) of 14.4 (16.6) months and a median of 8.7 months. The mean (SD) 2-year and 4-year AVR-free survival rates for asymptomatic patients with severe AS at baseline were 54% (2%) and 32% (3%), respectively. In those undergoing AVR, the 30-day postprocedural mortality was 0.9%. In patients with severe AS at entry, peak aortic jet velocity (greater than 5 m/s) and LVEF (less than 60%) were associated with all-cause and cardiovascular mortality without AVR; these factors were also associated with postprocedural mortality in those patients with severe AS at baseline who underwent AVR (surgical AVR in 310 patients; transcatheter AVR in 78 patients). CONCLUSIONS AND RELEVANCE: In patients with asymptomatic AS followed up in heart valve centers, the risk of sudden death is low, and rates of overall survival are similar to those reported from previous series. Patients with severe AS at baseline and peak aortic jet velocity of 5.0 m/s or greater or LVEF less than 60% have increased risks of all-cause and cardiovascular mortality even after AVR. The potential benefit of early intervention should be considered in these high-risk patients.
引用
- Lancellotti P, Magne J, Dulgheru R, et al. Outcomes of Patients With Asymptomatic Aortic Stenosis Followed Up in Heart Valve Clinics. JAMA Cardiol. 2018. PMID: 30285058. doi:10.1001/jamacardio.2018.3152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。